Filana Therapeutics, Inc. (FLNA) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

+230.5%

$1.85

vs $0.56 price

Levered DCF

$1.98

After debt service

Piotroski score

1 / 9

Weak

Altman Z-score

-7.4

Distress zone

Rating

B-

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
P/E	-1.09×	-3.87×	-0.88×	-1.08×	-2.5×	-8.54×	-7.59×	-3.36×
P/B	1.33×	0.65×	0.63×	0.36×	0.32×	0.58×	1.62×	1.12×
P/S	0×	0×	0×	0×	0×	0×	0×	0×
EV / EBITDA	-0.04×	0.24×	0.33×	1.48×	4.79×	3.61×	-1.32×	-0.32×
Gross margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Operating margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Current ratio	2.23×	11.62×	9.13×	29.91×	19.51×	50.4×	16.83×	39.22×
Debt / equity	0×	0×	0×	0×	0×	0×	0×	0×
Interest coverage	0×	0×	0×	0×	0×	0×	0×	0×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Return on equity	-122.3%	-16.7%	-70.7%	-33.5%	-12.8%	-6.9%	-21.0%	-33.4%
Return on invested capital	-128.0%	-97.0%	-77.1%	-35.1%	-12.9%	-11.9%	-43.7%	-33.9%
Return on assets	-76.9%	-15.5%	-64.1%	-32.5%	-12.1%	-6.7%	-19.7%	-32.6%
Free cash flow yield	-33.2%	-123.2%	-95.9%	-97.3%	-64.9%	-10.1%	-7.1%	-21.8%
Earnings yield	-91.9%	-25.6%	-113.1%	-92.5%	-40.1%	-11.8%	-13.0%	-29.9%
Enterprise value	$3.5M	-$33.6M	-$35.2M	-$118.5M	-$152.4M	-$39.7M	$12.7M	$2.1M
Net debt / EBITDA	1.06×	0.91×	1.14×	2.51×	7.32×	8.47×	2.39×	3×
Cash conversion cycle (days)	-2,495	0	0	0	0	-15,114	-2,851	-1,555